|
1
|
Tran T, Davila JA and El-Serag HB: The
epidemiology of malignant gastrointestinal stromal tumors: an
analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol.
100:162–168. 2005.
|
|
2
|
Miettinen M, Furlong M, Sarlomo-Rikala M,
Burke A, Sobin LH and Lasota J: Gastrointestinal stromal tumors,
intramural leiomyomas, and leiomyosarcomas in the rectum and anus:
a clinicopathologic, immunohistochemical, and molecular genetic
study of 144 cases. Am J Surg Pathol. 25:1121–1133. 2001.
|
|
3
|
Miettinen M and Lasota J: Histopathology
of gastrointestinal stromal tumor. J Surg Oncol. 104:865–873.
2011.
|
|
4
|
Centonze D, Pulvirenti E, Pulvirenti
D’Urso A, Franco S, Cinardi N and Giannone G: Local excision with
adjuvant imatinib therapy for anorectal gastrointestinal stromal
tumors. Tech Coloproctol. 17:571–574. 2013.
|
|
5
|
Christiansen J: Excision of mid-rectal
lesions by the Kraske sacral approach. Br J Surg. 67:651–652.
1980.
|
|
6
|
Koscinski T, Malinger S and Drews M: Local
excision of rectal carcinoma not-exceeding the muscularis layer.
Colorectal Dis. 5:159–163. 2003.
|
|
7
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004.
|
|
8
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998.
|
|
9
|
Jakob J, Mussi C, Ronellenfitsch U, et al:
Gastrointestinal stromal tumor of the rectum: results of surgical
and multimodality therapy in the era of imatinib. Ann Surg Oncol.
20:586–592. 2013.
|
|
10
|
Agaimy A, Vassos N, Märkl B, et al:
Anorectal gastrointestinal stromal tumors: a retrospective
multicenter analysis of 15 cases emphasizing their high local
recurrence rate and the need for standardized therapeutic approach.
Int J Colorectal Dis. 28:1057–1064. 2013.
|
|
11
|
Tielen R, Verhoef C, van Coevorden F, et
al: Surgical management of rectal gastrointestinal stromal tumors.
J Surg Oncol. 107:320–323. 2013.
|
|
12
|
Miettinen M, Sobin LH and Sarlomo-Rikala
M: Immunohistochemical spectrum of GISTs at different sites and
their differential diagnosis with a reference to CD117 (KIT). Mod
Pathol. 13:1134–1142. 2000.
|
|
13
|
Dematteo RP, Gold JS, Saran L, et al:
Tumor mitotic rate, size, and location independently predict
recurrence after resection of primary gastrointestinal stromal
tumor (GIST). Cancer. 112:608–615. 2008.
|
|
14
|
Connolly EM, Gaffney E and Reynolds JV:
Gastrointestinal stromal tumours. Br J Surg. 90:1178–1186.
2003.
|
|
15
|
Hassan I, You YN, Dozois EJ, et al:
Clinical, pathologic, and immunohistochemical characteristics of
gastrointestinal stromal tumors of the colon and rectum:
implications for surgical management and adjuvant therapies. Dis
Colon Rectum. 49:609–615. 2006.
|
|
16
|
Fu T, Liu B, Zhang S, Wang D and Zhang L:
Transvaginal local excision of rectal carcinoma. Curr Surg.
60:538–542. 2003.
|
|
17
|
Wang JP, Wang T, Huang MJ, Wang L, Kang L
and Wu XJ: The role of neoadjuvant imatinib mesylate therapy in
sphincter-preserving procedures for anorectal gastrointestinal
stromal tumor. Am J Clin Oncol. 34:314–316. 2011.
|
|
18
|
Matsushima K and Kayo M: Transsacral
approach to resect a gastrointestinal stromal tumor in the rectum:
report of two cases. Surg Today. 37:698–701. 2007.
|
|
19
|
Terkivatan T, den Hoed PT, Lange JF Jr,
Koot VC, van Goch JJ and Veen HF: The place of the posterior
surgical approach for lesions of the rectum. Dig Surg. 22:86–90.
2005.
|
|
20
|
Machlenkin S, Pinsk I, Tulchinsky H, et
al: The effect of neoadjuvant imatinib therapy on outcome and
survival after rectal gastrointestinal stromal tumour. Colorectal
Dis. 13:1110–1115. 2011.
|
|
21
|
Rutkowski P, Gronchi A, Hohenberger P, et
al: Neoadjuvant imatinib in locally advanced gastrointestinal
stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol.
20:2937–2943. 2013.
|
|
22
|
Eisenberg BL, Harris J, Blanke CD, et al:
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for
advanced primary and metastatic/recurrent operable gastrointestinal
stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg
Oncol. 99:42–47. 2009.
|
|
23
|
Verweij J, Casali PG, Zalcberg J, et al:
Progression-free survival in gastrointestinal stromal tumours with
high-dose imatinib: randomised trial. Lancet. 364:1127–1134.
2004.
|
|
24
|
Demetri GD, von Mehren M, Antonescu CR, et
al: NCCN Task Force report: update on the management of patients
with gastrointestinal stromal tumors. J Natl Compr Canc Netw.
8(Suppl 2): S1–S44. 2010.
|
|
25
|
Fujimoto Y, Akiyoshi T, Konishi T,
Nagayama S, Fukunaga Y and Ueno M: Laparoscopic
sphincter-preserving surgery (intersphincteric resection) after
neoadjuvant imatinib treatment for gastrointestinal stromal tumor
(GIST) of the rectum. Int J Colorectal Dis. 29:111–116. 2014.
|
|
26
|
Lagos AC, Marques I, Reis J, Martins I and
Neves B: Malignant rectal gastrointestinal stromal tumour: case
report and review of literature. J Gastrointest Cancer. Mar
8–2012.(Epub ahead of print).
|
|
27
|
Hara M, Takayama S, Arakawa A, Sato M,
Nagasaki T and Takeyama H: Transvaginal resection of a rectal
gastrointestinal stromal tumor. Surg Today. 42:909–912. 2012.
|
|
28
|
Gervaz P, Huber O, Bucher P, Sappino P and
Morel P: Trans-sacral (Kraske) approach for gastrointestinal
stromal tumour of the lower rectum: old procedure for a new
disease. Colorectal Dis. 10:951–952. 2008.
|
|
29
|
Lo SS, Papachristou GI, Finkelstein SD,
Conroy WP, Schraut WH and Ramanathan RK: Neoadjuvant imatinib in
gastrointestinal stromal tumor of the rectum: report of a case. Dis
Colon Rectum. 48:1316–1319. 2005.
|
